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Abstract
This review on the role of neuroﬁlaments as surrogate markers for axonal degeneration in
neurological diseases provides a brief background to protein synthesis, assembly, function
and degeneration. Methodological techniques for quantiﬁcation are described and a protein
nomenclatureisproposed.Therelevanceforrecognisinganti–neuroﬁlamentautoantibodies
is noted. Pathological implications are discussed in view of immunocytochemical, cell–
cultureandgeneticﬁndings.Withreferencetothepresentsymposiumonmultiplesclerosis,
the current literature on body ﬂuid levels of neuroﬁlaments in demyelinating disease is
summarised.
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The cytoskeleton of the axon is made of a scaffolding of proteins. Out of these the
most important are the neuroﬁlaments. Neuroﬁlaments are an architectonic amaz-
ingly stable tube system of about 10 nm diameter. This size places them interme-
diate between the smaller microﬁlaments (7 nm) and the larger microﬁlaments (¼
25 nm). Nf are classiﬁed as type IV intermediate ﬁlaments [1] (Table 1).
Table 1: Classiﬁcation of intermediate ﬁlaments and cell-type speci-
ﬁcity. GFAP = glial ﬁbrillary acidic protein. Adapted from [2].
Class Identity Cell–type speciﬁcity
Type I Acidic keratins Epithelial
Type II Neutral & Basic keratins Epithelial




Type IV NfL, NfM, NfH Neuronal
®–Internexin Neuronal
Type V Lamin A, B, C Most cells
Type VI Nestin CNS stem cells
To fully appreciate the structural achievement of this protein in cellular architecture
one must put the size of neurons and axons into relation. The neuronal cell–bodies
(0.01 to 0.05 mm size) are connected by axons of over 1m length (the axonal di-
ameter is 1 to 25 ¹m). This is a factor of 100,000 difference. How does the neuron
achieve to maintain this enormous structure, more importantly, how can the break-
down of the axon be detected and related to disease?
This review focuses on 4 parts; ﬁrstly the neuroﬁlament (Nf) subunit synthesis,
its assembly into tubular structure and the post–translational modiﬁcations with
particular reference to phosphorylation; secondly on methodological quantitative
techinques; thirdly on clinico–pathological relationships related to Nf disassembly
including accumulation, phosphorylation and disease; and ﬁnally the potential of
Nf to serve as surrogate markers for axonal injury, disintegration and loss with
particular reference to multiple sclerosis.
22 The Neuroﬁlament triplet protein
The dominant proteins of the axonal cytoskeleton are Nf. Nf are obligate het-
eropolymers that are composed of 3 subunits, a light (NfL), a medium (NfM) and
a heavy (NfH) chain (these are reviewed in detail by Lee and Cleveland [3]). Nf
are CNS cell-type speciﬁc proteins (Table 1) and qualify Nf as potential surrogate
markers of damage to neuron and axon.
2.1 Synthesis and assembly
NfL The Nf light chain (NfL) is coded on chromosome 8p21 and consists of 543
amino acids. The molecular mass corresponds to 61 kDa, but due to phosphoryla-
tion and glycosylation, migration in sodium dodecyl sulfate (SDS) polyacrylamide
gels (PAGE) is slow, and most authors refer to a molecular mass of 68 kDa as
determined in SDS–PAGE.
NfM The Nf medium chain (NfM) is also coded on chromosome 8p21 and con-
sists of 916 amino acids. The molecular mass is calculated as 102.5 kDa, and runs
at 150 kDa in SDS gels.
NfH TheNfheavychain(NfH)iscodedonchromosome22q12.2[4]andconsists
of 1020 amino acids. The molecular mass of the amino acids corresponds to 111
kDa. Most authors however refer to the molecular mass derived from SDS gels
which is also inﬂuenced by the charge/weight of bound phosphate and therefore
ranges from 190 to 210 kDa for the various phosphoforms.
Structure Each Nf subunit is composed of a highly conserved ®–helical core re-
gion of approximately 310 amino acids. The core region forms a double–stranded
coil, ﬂanked by the head (N–terminus) and the hypervariable tail (C–terminus)
domains [5] (Figure 1 A). The reason for the slightly confusing terminology for
protein head (carboxy–terminal) and tail (amino–terminal) is historical. The tail
of the NfM and NfH subunit protrude from the “head–to–head” assembled poly-
mer. The ®–helical rod domain is mainly relevant for Nf assembly, whilst the
variable head and tail domains are responsible for functional properties such as
protein–protein interactions, with the head–domain also contributing to assembly
[6, 7, 8, 9]. Cross–linking and interaction of the assembled heteropolymers with
other cytoskeletal proteins depends mainly upon the C–terminal NfH tail domain
and is of functional importance (Figure 1 B).
3(A) Neurofilament Isoforms
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Figure 1. (A) The neuroﬁlament protein subunits. The amino-terminal head domain is of
variable length whilst the central rod and carboxy-terminal tail domain remain constant.
The calculated molecular weights and the molecular weights as determined by SDS gel
electrophoresis (in brackets) are shown.
(B) Functional properties of the neuroﬁlament protein such as cross-linking and pro-
tein–protein interactions are controlled locally in the axon by phosphorylation and
dephosphorylation.
The formation of the typical IF of 10 nm diameter is determined by the correct as-
sembly of the NfL, NfM and NfH subunits. The assembly of the three Nf subunits
is dependent on the N–terminal head region. NfL is known to polymerise on its
own in vitro, while NfM and NfH cannot [10]. However, both NfM and NfH can
co–assemble with NfL in vitro [11]. Assembly occurs in 5 stages: polypeptides are
wound around each other to form dimers which are sorted in an antiparallel fashion
in order to form tetramers, protoﬁlaments and ﬁnally IF (Figure 2). The ®–helical










































Figure 2. Neuroﬁlament assembly. The central rod domain of the Nf subunits is intertwined
in order to form dimers. The dimers are sorted antiparallel and form tetramers. Tetramers
combine to form protoﬁlaments, which ﬁnally assemble to produce the 10 nm thick Nf.
Ultrastructural analysis of the NfL assembly process reveal that the lateral asso-
ciation of the protoﬁbrils is promoted by the head–domain and terminated by the
tail–domain [13]. In vivo Nfs are obligate heteropolymers [12].
Phosphorylation The neuroﬁlament heavy chain is the most extensively phos-
phorylated protein of the human brain, and possibly the entire human body. Phos-
phorylation and dephosphorylation of the neuroﬁlament proteins is a complex pro-
cess which is predominately regulated within the axonal compartment and tar-
geted on different phosphate acceptor sides in the Nf subunits (Figure 3) [14, 15].
NfMandNfHbecomehighlyphosphorylatedpost–translationallyafterbeingtrans-
ported from the neuronal cell soma in the axon. In vivo phosphorylation of Nf is
slow, orchestrated by a range of enzymes and has recently been reviewed in detail
by Grant & Pant [16]. In brief, enzymatic phosphorylation is predominantly sub-
ject to 2 types of kinases: the non–proline directed and the proline directed (i.e.
cyclin–kinases and MAP kinases).
Phosphorylation of the C–terminal tail domain is thought to occur at the side arms






















































































































































































































































































































































































Figure 3. The main phosphorylation sites of different kinases on the three Nf proteins are
shown (adapted from [16]).
42 KSP (Lys-Ser-Pro) repeats in humans [17, 18, 19]. Phosphate is coupled with
high afﬁnity to serine within the KSP repeats [18, 19]. An additional phosphate
acceptor site with high binding afﬁnity is threonine [16].
The N–terminal domain is phosphorylated by glycogen synthetase kinase-3 [20,
21], extracellular signal-regulated kinases [22, 23] and cyclin-dependent kinase-5
[14, 24, 25].
Phosphorylation of the C–terminal domain is regulated by a range of protein ki-
nases [6, 26, 27].
Glycosylation The NfL (Ser27, Thr21) and NfM (Thr48) head region are post–
translationallymodiﬁedbyaddingonO–linkedN–acetylglucosaminemoieties[28].
All these locations are essential for in vivo Nf assembly. O–GlcNAc modiﬁcation
has also been reported for the NfH KSP repeats [29], but the precise sites have not
yet been identiﬁed. It is possible that glycosylation plays a role in Nf trafﬁcking
and function.
Terminology Since the use of speciﬁc monoclonal antibodies permits us to detect
distinct Nf epitopes, the distribution of different NfH phosphoforms was studied in
axonal pathology and in neurodegeneration. It is against the background of this
research that Sternberger et al. (1985) proposed the classiﬁcation of the antibodies,
6recognising these NfH phosphoforms according to their cellular distribution into 4
groups: Group I antibodies stain cells and structures in the grey matter, Group II
antibodies stain for projecting axons, but not for neuronal perikarya, dendrites or
proximal axons, Group III antibodies stain for perikarya, dendrites and proximal
axons and Group IV antibodies stain for all structures revealed by group II and
group III antibodies [30].
However, in the literature reference is commonly made to non–phosphorylated or
hypophosphorylated versus hyperphosphorylated or extensively phosphorylated,
with phosphorylated being the assumed dominant (normal) NfH phosphoform. The
use of mass–spectroscopy permits the identiﬁcation of the phosphorylation sites
within the protein [18, 19]. This requires labour–intensive pre–analytical puriﬁca-
tion of Nf sub-units [18] and because of conformational changes correct identiﬁca-
tion of non–linear epitopes cannot be guaranteed.
The pragmatic approach proposed here is to classify NfH phosphoforms (NfHp)
by naming the detecting antibody in superscript. In other words, if NfH was de-
tected by the Sternberger monoclonal antibody SMI32 this NfH phosphoform is
labelled NfHSMI32. Likewise when phosphorylated NfH, was detected by the bind-
ingtoaphosphorylatedepitoperecognisedbytheSternbergermonoclonalantibody
SMI35, this is labelled NfHSMI35. A complete Table of the proposed nomenclature
is given in [31]. For each antibody the name of the clone and the source need to be
provided. This terminology facilitates comparisons of results between studies and
across methods (i.e. immunoblotting, immunocytochemistry and ELISA).
Function About 80% of axonal Nf are highly phosphorylated and integrated by
cross–linking in the axoskeleton, thus constituting the “static pool” [32]. The re-
maining 20% of less extensively phosphorylated Nf constitute the so called “dy-
namic pool” [33, 32].
Because phosphorylation alters the charge of the side–arms, it was proposed that
one function of phosphorylation is to increase the charge–based repulsion of neigh-
bouring ﬁlaments, thereby increasing inter-ﬁlament spacing and consequently in-
creasing axonal calibre [34]. The close relation of axonal diameter and conduction
velocity [35, 36] is of physiological relevance.
However, radial axonal growth does not depend on mechanisms of NfH phospho-
rylation alone [37] and the original hypothesis, that phosphorylation of NfH side–
arms is essential for Nf spacing and radial axonal growth, has been modiﬁed in that
Nf subunits interact stoichiometrically and NfM is the “preferred” subunit for NfL
copolymerisation and main regulator of radial axonal growth [38, 39, 40, 41]. It
also seems that NfL and NfM stoichiometrics are more important for axonal growth
than NfH phosphorylation. This notion is substantiated by knockout mice experi-
ments [38, 41, 42, 43, 44, 14, 45] (for review see [16, 14]). It was suggested that
7small side–arms extend from non–phosphorylated NfH, but extend much further
with phosphorylation and charge–related uncoiling of the KSP repeats [46]. Whilst
non–phosphorylated NfH adhere to microtubules,probably in competition with tau,
phosphorylation leads to dissociation from the microtubules [47, 48]. Other IF–
interacting proteins are mainly from the plakin family (i.e. the bullous pemphigoid
antigen–1 proteins (BPAG1), ACF7, desmoplakin, envoplain and periplakin), the
dynein/dynactin complex, myosin Va and probably the D(1) dopamine receptor
(reviewed in [49]). Lee and Cleveland suggested that “the phosphorylation process
is ultimately linked to, and may be regulated by, myelination.” [3, p. 204].
The importance of local phosphorylation for regulating Nf assembly is highlighted
by the observation that the formation of protoﬁbrils is inhibited if the NfL head
domain becomes phosphorylated [50, 51]. In fact phosphorylation of the NfL head
domain at Ser55 or the NfM head domain at Ser44 by protein kinase A (PKA) is
sufﬁcient to block Nf assembly [6, 27].
The relatively small (¼ 20%) “dynamic pool” of non- or hypophosphorylated NfH
[33, 32] is involved in ante- and retrograde axonal transport [52].
Axonal transport The initial studies of axonal transport of Nf using radiographic
labelling [53, 54, 55] suggested a velocity of ¼ 0.25–3 mm/d which is slower than
any speed produced by known molecular motors [56, 49]. Recent studies using
green–ﬂuorescent–protein (GFP)–tagged Nf subunits and real–time confocal mi-
croscopy show more accurately that the conventional fast axonal transport also
applies to Nf. Peak velocities of 2 /second occur antero- and retrograde and are
interrupted by prolonged resting phases resulting in the overall slow transport orig-
inally described (reviewed in [57, 49]).
The degree of phosphorylation correlates inversely with the velocity of axonal
transport [58, 59, 60]. It has been suggested that this is due to phosphorylation
dependent dissociation of Nf from the kinesin motor [61].
Accumulation of Nf has been shown in a range of diseases. Recent work using
GFP–tagged NfM demonstrated in cell–culture (SW13) that treatment with gluta-
mate slows axonal transport and leads to neuronal accumulation of NfHSMI36 [62].
This ﬁnding supports the concept that glutamate–induced excitotoxicity might con-
tribute to the pathogenic process in some neurodegnerative diseases.
Degradation It is believed that Nf are broken–up when they arrive at the axon
terminus. The breakdown of Nf depends on protease digestion [63, 64]. Under
physiological conditions this is mediated by calmodulin, a Ca2+–dependent pro-
tease [65]. Susceptibility of Nf to protease digestion decreases with increase of
phosphorylation [66, 67, 68]. This has analytical implications, particularly for NfL
8and the non–phosphorylated forms of NfM and NfH in protease–rich body ﬂuids
such as the cerebrospinal ﬂuid (CSF).
Lee and Cleveland calculated the life-time of Nf to be around 1–2 years, based on
calculating the transit time through the human sciatic nerve at a daily rate of 1–
2 mm/day [3, p. 202]. Because of this long–life Nf are very likely to accumulate
damage caused by oxidative stress, inﬂammation, etc. which could ultimately lead
to disturbed ﬁlament assembly, accumulation and axonal pathology.
There might be a biological reason why NfL is more susceptible to protease activity
then NfH and NfM. The potential of NfL to polymerise on its own could result in
protein accumulation, aggregate formation and disease.
93 Methodological approaches
At present three methodological approaches have been undertaken in an attempt
to quantify Nf: (1) Western / immunoblotting techniques [67, 69], (2) a dot–blot
immunoassay [70] and (3) ELISA techniques [71, 72, 31, 73].
Western & dot blotting Although of qualitative advantage for distinguishing
NfH phosphoforms and breakdown products, the Western/immuno–blotting tech-
niques have never been adopted on a clinically relevant scale. This is partly due
to the semiquantitative and labour intensive nature of the method. It is particularly
difﬁcult to overcome the densitometric limitations of highly sensitive methods such
as chemiluminescence because of the high gamma of photographic paper which re-
sults in a steep standard curve with a very small linear range. New charged–double
device (CDD) cameras which enable one to obtain serial images could help to over-
come this problem [74]. The trouble with a dot–blot approach is speciﬁcity which
impacts on CV and reproducibility. In contrast the ELISA approach provides the
highest analytical accuracy and is ideal for a high throughput of samples.
ELISA TwoNfsubunitshavebeeninvestigatedinhumanbodyﬂuidsusingELISA:
NfL [71, 73] and NfH [72, 31]. The Lars Rosengren group concentrated for over
10 years on NfL with good reason: this Nf protein is considered to represent the
most abundant subunit, hence the term “backbone” of the Nf polymer. It also is
the smallest and most soluble subunit. These requirements would make it an ideal
candidate for a surrogate marker if it were not for some concerns about its suscep-
tibility to proteases, particularly in the protease–rich CSF. Thus rigorous sample
handling is recommended (i.e. snap–freezing of the CSF at the bedside).
Because of the associated logistical problems our group has concentrated on NfH,
which in its phosphorylated state is more resistant to proteases [66, 31, 67, 68].
Additionally NfH phosphorylation is of functional importance in axonal pathology.
Information on the quantitative relationship of NfH phosphoforms might provide
further insight in the dynamics of axonal injury and thus contribute to our under-
standing of neurodegenerative diseases.
Autoantibodies It is of note that the presence of neuroﬁlament auto–antibodies
hasbeenobservedbyseveralgroups[75,76,77,78,79],mainlyinchronicdiseases.
Because Nf auto–antibodies potentially decrease body ﬂuid antigen levels, they
could inﬂuence the quantiﬁcation of Nf by ELISA or other methods and should
ideally be measured in order to allow for a balanced interpretation of the data.
104 Axonal pathology
Nf subunits are actively involved in the pathogenesis of axonal dysfunction and
degeneration both as causative agents for disease and as markers for disease pro-
gression.
4.1 Neurology of Nf
It has been suggested the neurology of Nf be classiﬁed into disorders of Nf synthe-
sis, phosphorylation, distribution by axonal transport, and their breakdown [80].
The accumulation of Nf proteins has been observed in amyotrophic lateral sclero-
sis (ALS, synonymous with motor neuron disease) [81], spinal muscular atrophy
[82], Parkinson’s disease (PD), some dementias (as a component of Lewy bodies
together with ®–synuclein), Alzheimer’s disease (AD), progressive supranuclear
palsy (PSP), diabetic polyneuropathy and giant axonal neuropathy [83].
Multiple sclerosis In MS, axonal injury has been related to increased staining
by NfHSMI32 [84, Figure 8B]. NfHSMI32 was particularly abundant in axonal ovoids
which indicate the site of axonal transection. With regard to cortical lesions B¨ o pro-
vided evidence for axonal loss by demonstrating the frequent occurrence of ovoids.
Interestingly, and in contrast to the ﬁnding by Trapp et al. [84], the intensity of
staining of non–phosphorylated NfH (NfHSMI32 ) was reduced in most cortical re-
gionsofaxonswithmyelinloss,whilststainingforphosphorylatedNfH(NfHSMI34 )
increased [85]. One might speculate that this difference in patterns of NfH phos-
phorylation reﬂects differences in patterns of damage, i.e. Wallerian degeneration
in white matter pathology versus dying back neuropathy in grey matter pathology.
Alzheimer’s disease In AD, increased staining for phosphorylated NfH is evi-
dent in the proximal axon and the perikaryon [30, 86, 87, 88]. The NfH phosphory-
lation in axons elongating from AD plaques is particularly intriguing and has been
interpreted as evidence of early axonal injury caused by toxic properties of the
plaque [67, 87, 88]. Others provided evidence that NfHSMI32 positive neurons are
selectively lost in AD [89, 90, 91]. This ﬁnding was supported by demonstrating
kainate–dependent hyper-vulnerability of NfHSMI32 positive neurons [91].
Amyotrophic lateral sclerosis In ALS, increased staining for phosphorylated
NfH (i.e. NfHSMI34 , NfHSMI35 ) has been shown in axons and the neuronal cell
11bodies. There is evidence for accumulation of phosphorylated NfH in the degen-
erating motor neurons [81, 92]. However, Nf dephosphorylation has also been re-
ported to precede excitotoxicity in a spinal cord cell culture model of ALS [93, 94].
Extending this work, the same group has recently reported an increase in staining
for NfHSMI32 of cultured spinal cord neurons after exposure to CSF from patients
with ALS [95]. Interestingly 3 of the 6 control CSF samples were from patients
with MS, but the breakdown of the individual data was not published [95]. The
implications of Nf aggregation, mainly in the neuronal cell body, is a prominent
feature of ALS and has been studied in depth mainly by Jean Pierre Julien’s group
using the gain of function SOD¡ mouse (for review see [96, 97, 98, 99]). It seems
that somal accumulation is preceded by disruption of axonal Nf transport due to
stoichiochemical imbalance of the Nf subunits. However the pathological impli-
cations of somal accumulations are not entirely clear and the same group holds a
patent protecting one approach to using Nf phosphorylation as a neuroprotective
strategy.
Cerebrovascular pathology In stroke, Hedreen and colleagues demonstrated ac-
cumulation of phosphorylated NfH (NfHSMI35 , NfHSMI34 , NfHSMI31) in neuronal
cell–bodies and dendrites which were likely to have suffered from axonal discon-
nection in stroke (i.e. in the thalamus and cerebral cortex) [100]. This phenomenon
was observed up to 2 months after a stroke. The authors suggested impaired axonal
transportasthepathologicalcorrelate.Inarecentstudyonintracranialandsubdural
haemorrhage we found an increase of the phosphorylated (NfHSMI34 , NfHSMI35 ,
NfHSMI310 ) but not of the non-phosphorylated (NfHSMI310 ) protein [101].
Glaucoma The monkey model of glaucoma is the only other condition apart
from MS [84] where, to the best of my knowledge, increased staining of non–




NfH NE14 ratio was used to calculate the phosphorylation status (a high ratio
indicating a high degree of phosphorylation). In the glaucomatous eye there was
a decrease in staining for NfHSMI31 in the retina, the optic disc and optic nerve
reaching as far back as the optic chiasm. There was a 4-fold difference in the de-
gree of phosphorylation in all but the nasal retina, ranging from ¼ 21–53% in the
glaucomatous to 85–97% in the control eyes. This semiquantitative ﬁnding is sup-
ported by Western blot analysis showing a stronger band for NfHSMI32 in tissue
homogenate from the glaucomatous eye. The authors speculate that this might be
related to disturbance of axonal transport, a well known phenomenon in glaucoma,
but leave it open as to whether NfH dephosphorylation is “the chicken or the egg”







































































































































































































































































































all instertions or deletions 22q12.1 to q13.1
Pro22Ser Glu397Lys
Figure 4. Mutations in the NfL, NfM and NfH subunit cause Charcot–Marie–Tooth (CMT)
disease, Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). Adapted and
updated from [57].
Charcot–Marie Tooth disease CMT is an inherited neuropathy comprising a
rangeofgeneticclassiﬁcations(forreviewsee[103,104]).Theaxonalform(CMT2E)
has been associated with mutations in the rod domain of the NfL subunit [105, 106,
107,108,109](Figure4).Mutation closetotheNfLrod–domaincauses anincrease
of neuronal NF-L due to impaired Nf assembly [110]. Whether the problem is pri-
marily due to increased axonal vulnerability caused by impaired axonal transport
[110] or to cytoskeletal instability remains to be clariﬁed.
Parkinson’s disease In PD a single case report with a point mutation in the rod
domainofNfMhasbeenreported[111].However,threeunaffectedmembersofthis
family also carried the same mutation. The link between genotype and phenotype
remains to be proven.
Diabetic neuropathy This is mostly of the symmetrical sensory distal axonal
type. An increase of Nf phosphorylation has been observed in humans [112] and
in the lumbar dorsal root ganglia of rats with streptozocin–induced diabetes [113].
It has been suggested that activation of c–Jun NH2–terminal kinase (JNK) plays a
role in this process.
13Giant axonal neuropathy The hallmark of giant axonal neuropathy (GAN) is
the segmental axonal accumulation of Nf [83]. This is due to multiple mutations
on chromosome 16q24.1 encoding for gigaxonin [114]. Gigaxonin is a 597–amino
acid BTB (Broad–Complex, Tramtrack and Bric–a–brac)/Kelch protein. It has been
suggested that gigaxonin serves as an IF association protein [80]. Gigaxonin dis-
ruption leads to Nf disorganisation and massive multifocal Nf accumulation.
Miscellaneous conditions Giant axonal swellings have also been observed in
iminodipropionitrile(IDPM)and2,5–Hexanedione(glue–snifﬁng)neuropathy[80].
Others observed increased NfH phosphorylation in opiate addiction in humans
[115] and mice [116].
4.2 NfH phosphorylation status and disease
In order to obtain more information on the NfH phosphorylation status several
authors stained for phosphorylated (e.g. NfHSMI34 ) and non–phosphorylated (e.g.
NfHSMI32 ) pre– and post–enzymatic dephosphorylation with alkaline phosphatase
(ALP) [117, 67, 30, 118, 119, 87, 88, 119, 86]. The results of these experiments
have been summarised for the non–phosphorylated NfH SMI epitopes in Table 2 &
3. For each NfH phosphoform the antibody source and main effects as observed by
immunocytochemistry were summarised with regard to ALP–treated versus non–
treated tissue sections. Because the applied method of dephosphorylation varied
considerably (e.g. incubation times from 2.5 to 18 hours), the protocol is referred
to in the footnotes of Tables 2 and 4. It is worthwhile remembering that ALP used
in all of these experiments was not 100% pure and a certain degree of NfH pro-
teolysis due to contamination with proteases is possible, particular for the longer
incubation periods (i.e. 18 h at 32±C).
The results are contradictory, on one side non–phosphorylated NfH (i.e. NfHSMI32 )
seems to indicate either vulnerable neurons or injured axons in diseases such as
MS, glaucoma, ALS and AD [84, 93, 94, 95, 89, 90, 91]. On the other side phos-
phorylated NfH (i.e. NfHSMI34 or NfHSMI35 ) is related to axons injured by plaque
toxicity, to neuroﬁbrillary tangles (NFT) [120, 87, 88, 30, 86], an axon–proximal
ﬁnding in dementia [119, 92, 81, 30, 87, 88, 86], indicative of axonal damage in
stroke [100], a hallmark of GAN [83].
The puzzle of whether increased or decreased Nf phosphorylation indicates axonal
injury is unsolved. The ﬁeld is open to speculation on disease chronicity, impair-
ment of axonal transport, enzymatic imbalance, etc.
14Table 2: Non–phosphorylated Nf stained in immunocytochemistry by the SMI
clones. Characterisation of the antibody staining pattern in untreated and ALP
treated sections. N.D. = not determined, N/A = not available/ data was not
shown, GM = grey matter, WM = white matter, + = positive, - = negative, #
less intense after ALP treatment.
Antibody Model Not treated ALP Treated
NfHSMI32 ctrl thick axons (+) [67, 117, 118] thick axons (+) ¤
NfHSMI32 ctrl neuron/dendrites (++) [67, 117, 118] neuron/dendrites (++)
NfHSMI32 cell culture vulnerable GABAergic axons (+++) [91] N.D.
NfHSMI32 MS demyelinated axons (+++) [84] N/A
NfHSMI32 MS axonal ovoids (+++) [84] N/A
NfHSMI32 AD plaques (+) [87] plaques +++
NfHSMI32 AD dystrophic neurons (+) [88] ++ y
NfHSMI33 AD data not shown [88] N/A
NfHSMI33 AD GM ++: AD = CTRL [120] N.D.
NfHSMI33 AD WM +: AD = CTRL [120] N.D.
NfHSMI33 AD pyramidal neurons, no NFT +++: AD <<< CTRL [120] N.D.
NfHSMI33 AD pyramidal neurons, with NFT +: AD = CTRL [120] N.D.
NfHSMI33 ALS Spine: ctrl > ALS [119] staining ## z
¤ Alkaline phosphatase treatment: 43¹L calf intestinal alkaline phosphatase (type VII,
Sigma) per mL in 0.1 M Tris–HCl, pH 8.0, 0.01 M phenyl-methylsulfonyl ﬂuoride, at 32±C
for 18 hours.
y Alkaline phosphatase treatment: 400 ¹g/mL calf intestinal alkaline phosphatase (type
VII, Sigma) in 0.1 M Tris–HCl, pH 8.0, at 37±C for 1.5–2 hours.
z Alkaline phosphatase treatment: 400 ¹g/mL calf intestinal alkaline phosphatase (type
VII, Sigma) in 0.1 M Tris–HCl,0.01 M phenylmethylsulfonylﬂuoride, pH 8.0, at 32±C for
2.5 hours. Similar results were found for pretreatment with trypsin (GIBCO), 400 ¹g/mL
in 0.05 M Tris–HCL, 0.3 M sodium chloride, 0.02 M CaCl, pH 7.6, 37±C for 10 minutes.
15Table 3: Phosphorylated Nf stained in immunocytochemistry by SMI clones.
Characterisation of the antibody staining pattern in untreated and ALP treated
sections.
Antibody Model Not treated ALP Treated
NfHSMI31 ALS Brain: ctrl > ALS [119] staining ##
NfHSMI31 AD GM +: AD = CTRL [120] N.D.
NfHSMI31 AD WM +++: AD = CTRL [120] N.D.
NfHSMI31 AD pyramidal neurons, no NFT —: AD = CTRL [120] N.D.
NfHSMI31 AD pyramidal neurons, with NFT —: AD = CTRL [120] N.D.
NfHSMI31 AD data not shown [87] N/A
NfHSMI31 AD (+) [88] N/A
NfHSMI34 ctrl thick axons (+++) [67, 117, 118] staining abolished
thin axons (++) [67, 117, 118] staining abolished
basket cell dendrites (+) staining abolished
NfHSMI34 AD GM §: AD = CTRL [120] N.D.
NfHSMI34 AD WM §: AD = CTRL [120] N.D.
NfHSMI34 AD pyramidal neurons, no NFT —: AD = CTRL [120] N.D.
NfHSMI34 AD pyramidal neurons, with NFT +++: AD >>> CTRL [120] N.D.
NfHSMI34 ALS Spine: ctrl = ALS [119] staining ##
NfHSMI34 ALS Brain: ctrl >> ALS [119] staining ##
NfHSMI35 ALS Brain: ALS >>> CTRL [119] staining ##
NfHSMI35 ctrl thick axons (++)[67, 117, 118] staining reduced
NfHSMI35 ctrl thin axons (+++) [67, 117, 118] staining reduced
NfHSMI35 ctrl neuron/dendrites (+/—) staining abolished
NfHSMI35 AD GM +: AD = CTRL [120] N.D.
NfHSMI35 AD WM ++: AD << CTRL [120] N.D.
NfHSMI35 AD pyramidal neurons, no NFT —: AD = CTRL [120] N.D.
NfHSMI35 AD pyramidal neurons, with NFT ++: AD >> CTRL [120] N.D.
NfHSMI310 ALS inconsistent results [119] staining ##
16AD intraneuronal tangles (++) [30, 86] staining abolished
NfH–P stroke early neuronal damage ++ [100] N.D.
17Table 4: Neuroﬁlament antibodies other than then the SMI clones used for
immunocytochemistry. N4142 was a rabbit polyclonal anti-NfH from Sigma.
Antibody Model Not treated ALP Treated
NfHN4142 AD data not shown [87] N/A
NfHRT97 [121] AD Cerebellum + [122] staining # ¤
NfHRT97 [121] AD Hippocampus + [122] staining ##
NfHRT97 [121] AD Hippocampus NFT + [122] staining #
NfHRT97 [121] nerve injury +++: neurons with crushed nerves >>> CTRL [123] N.D.
NfHBF10 [121] AD Cerebellum + [122] staining #
NfHBF10 [121] AD Hippocampus + [122] staining #
NfHBF10 [121] AD Hippocampus NFT + [122] +
NfHBF147 [121] AD Cerebellum + [122] staining #
NfHBF147 [121] AD Hippocampus + [122] staining ##
NfHBF147 [121] AD Hippocampus NFT — [122] staining —
NfH1D[124] CJD swollen neurons: + [125] — y
NfH–P WHD early damage in LMN ++ [126] N.D.
NfHmab1:1:1 [127] AD AD +, CTRL: — [128] N.D.
NfHMAB147 [121] tractotomy affected neurons: + [129] N.D.
Anti–Nf auto–antibodies The presence of human anti–Nf auto–antibodies has
been studied in a range of diseases. This might be of particular importance in
¤ Alkaline phosphatase treatment: 100¹L calf intestinal alkaline phosphatase (Supplier not
given) in 0.1 M Tris–HCl, pH 8.0, at 37±C for 2.5 hours.
y Alkaline phosphatase treatment: 20 IU/mL alkaline phosphatase (Supplier not given) in
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Figure 5. Levels of NfHSMI35 ng / mg protein in homogenised neurons, astrocytes and
microglia (mean§SD). Adapted with permission from [31].
chronic diseases where accumulation of axonal degeneration leads to continuous
Nf release and consequently to stimulation of the humoral immune–system. These
may interfere with ELISA.
Nf–autoantibodies have been found in multiple sclerosis [75, 76], as a cause for
conduction block in neuropathy with monoclonal gammopathy of undetermined
signiﬁcance [77], in patients with rheumatoid arthritis and neuropathy [78] and in
ALS [79]. It is beyond the scope of this manuscript to review the literature of anti–
Nf autoantibodies other than reminding readers of their existence.
4.3 Cross–validation of quantitative approaches estimating axonal loss
For a Nf ELISA to be used for estimating axonal degeneration and loss in vivo,
two experiments need to be carried out: ﬁrstly it must be shown that Nf is present
exclusively in the neuro–axonal compartment, thus Nf cannot be released from
other cell–types (cell–type speciﬁcity); secondly a correlation should exist between
tissue axonal count and Nf levels in tissue homogenate.
Cell–type speciﬁcity was demonstrated for NfHSMI35 using primary neuronal, as-
trocytic and microglial cell–cultures (Figure 5) [31]. However after publishing the
method I noticed a report on the presence of NfH in T–lymphocytes [130] and em-
bryonic heart muscle [131]. Thus proof that all body ﬂuid NfHSMI35 is truly due to
axonal disintegration remains to be obtained. Whilst contamination might be negli-
gible for the CSF this is an important experiment to be carried out for interpretation
of blood levels of any of the Nf subunits.
































Figure 6. (A) Immunocytochemistry on longitudinal fresh frozen spinal cord sections of 3
control and 3 CREAE animals (x40). NfH staining in white matter. Axonal tracts can be
followed in control but not in CREAE animals. The staining in CREAE animals is less in-
tenseandmanyaxonalend-bulbsareseen.(B)Micespinalcordtissuehomogenates.Scatter
and box-whisker plot for NfHSMI35 (ng/mg protein). Adapted reprint with permission from
[132].
cords from mice with chronic relapsing experimental autoimmune encephalomyeli-
tis (CREAE) was demonstrated [132]. Figure 6 (A) demonstrates the near complete
loss of axonal continuity, presence of axonal end–bulbs and almost abolished ax-
onal presence in the atrophied spinal cord from CREAE mice. Analysis of this
spinal cord tissue homogenate showed that levels of NfHSMI35 corrected for the
amount of total protein were signiﬁcantly lower in CREAE animals compared to
controls, suggestive of axonal loss (Figure 6).
5 Nf as a surrogate marker for axonal injury in MS
The hypothesis underlying the measurement of Nf as a surrogate marker for ax-
onal damage is outlined in Figure 7. The following headings are arbitrary and only





























































































































































































































































































































































































































































































































































































































































































































































Figure 7. Neuroﬁlaments are released into the extracellular ﬂuid during axonal disintegra-
tion following axonal injury. Conduction block (e.g. by anti–NfH autoantibodies [77]) and
demyelination are potentially reversible whilst axonal loss is not.
5.1 CSF NfL studies
The acyclovir trial The ﬁrst paper investigating the potential of Nf as a surro-
gate marker for axonal injury in MS was published by Lycke and colleagues. The
authors measured NfL CSF levels in patients with relapsing remitting disease par-
ticipating in a trial with acyclovir [133]. These 60 patients had a mean disease dura-
tion of 5.8 years, a mean age of 33 years and an EDSS of < 4. None of the controls
(11 healthy volunteers) and 78% of the RRMS patients had detectable CSF NfL
levels. Absolute values were not given, but estimating from [133, Figure 1] mean
CSF NfL levels are about 990 ng/L in the ﬁrst month after relapse and level at ¼
200-400 ng/L three months later.
21The acute relapse study In a subsequent paper the same group obtained ethi-
cal approval to recruit 66 MS patients and 50 healthy volunteers (blood donors)
for CSF sampling [134]. 23 patients suffered from a relapse (RRMS–rel) in the 3
months prior to sampling, 18 were in remission (RRMS–rem) and 25 had SPMS.
TheSPMSpatientswereolder(mean47.7years)thantheRRMS–rel(32.4),RRMS–
rem (47.7) and controls (35.4). CSF NfL was determined using the same ELISA
method as in 1998 [71], the only difference being that non–detectable values were
substituted by 125 ng/L (the assay’s sensitivity) [134]. CSF NfL levels were de-
tectable in 8% of the controls, 48% of SPMS, 44% of RRMS–rem and 91% of
RRMS–rel. Absolute values for the subgroups were not given, but estimating from
[134, Figure 1] median levels for SPMS are ¼ 0 (0 - 625) ng/L, RRMS–rem ¼
(0 - 750) ng/L and RRMS–rel ¼ (0 - 4,875) ng/L. Of note is that in one subgroup
(n=13) of the RRMS–rel patients follow–up CSF was available. Median CSF NfL
levels were 1,877 ng/L (median of 16 days post–relapse), 2,699 ng/L (34 days) and
2,017 (105 days).
The MS siblings study The retrospective study aimed to investigate whether in-
dividuals with MS immunopathic trait showed early biochemical signs of early in-
volvement of axons [135]. A total of 47 MS patients, 47 siblings (9 with MS trait)
and 50 healthy controls (presumably the same as in [134]) were included. The mean
age of the MS patients (44 years) or their siblings (44–45 years) was signiﬁcantly
higherthaninthecontrols(33years).MSpatientshadsigniﬁcantlyhigherCSFNfL
levels (mean§SD 258.7§186.7 ng/L) than either their siblings (140.8§49.0 ng/L)
or the healthy controls (128.3§15.8 ng/L). The authors elegantly applied Fisher’s
permutation test for statistical analysis.
The new NfL ELISA Using a new ELISA method Rosengren and colleagues
found CSF NfL levels above cutoff (100 ng/L determined as mean + 3 SEM of the
control group) in 2/11 (18%) healthy volunteers (mean§SEM 31§23 ng/L) and 4/5
(80%) of RRMS patients (2,500§1,500 ng/L) [73].
The dot–blot study Another group investigated NfL levels using a dot–blot im-
munoassay [70]. Sixteen patients with RRMS, 13 with SP MS and 6 with PPMS
have been included. The age distribution was (mean§SD) 32.6§5.3, 45.3§4.2 and
41.2§7.4 years, respectively. The control group consisted of 11 “healthy” individu-
als(8spinalanaesthesiaduringlabourand3withnon–speciﬁcheadacheorneurotic
syndromes, mean age 22.5§3.2 years). Absolute values were not given but approx-
imating [70, Figure 4] 24/35 (69%) of the MS patients had values above cutoff (¼
145 CSF NfL units/mg protein). The mean value for the controls was ¼ 100 NfL
units/mg protein, for RRMS ¼ 170 NfL units/mg protein and for SP/PPMS ¼ 200
NfL units/mg protein. Levels in RRMS and SP/PPMS patients were signiﬁcantly
higher than in the total group.
225.2 CSF NfHSMI35 studies
The NfH ELISA CSF NfH was also measured in 36 patients with laboratory–
supported demyelinating disease (MS, CIS, ON) [31]. Based on a cut–off of 0.73
ng/mL derived from 416 patients with other neurological diseases only 1/36 (3%)
had pathologically high CSF NfH levels, with the median level being 0.27 (0-0.36)
ng/mL. The relapse free interval of this group was not recorded but all patients un-
derwent diagnostic lumbar puncture following acute onset of neurological symp-
toms suggestive of a relapse–proximate LP.
The Amsterdam cohort — baseline The patients in the Amsterdam group had
more benign MS than the above group, and were recruited following an announce-
ment in response to an appeal in the periodical of the Dutch MS Society [76]. From
65 responders 51 patients fulﬁlled the diagnosis of MS according to the Paty crite-
ria and agreed to undergo a LP. The median age was 46.3 years for all MS patients
with RRMS being the youngest (40.0 years), followed by SPMS (46.2 years) and
PPMS (51.0 years). The EDSS was 3.5, 1.75, 6.0, 6.0, respectively. The relapse
free interval was substantially longer than in the other studies, 36.5 (all patients),
15.0 (RRMS), 77 (SPMS) months. Median CSF NfH levels were 0.05 (interquartile
range 0.02–0.15) ng/mL for all MS patients, 0.07 (0.02–0.15) ng/mL for RRMS,
0.04 (0.02–0.17) ng/mL for SPMS and 0.09 (0.02–0.13) ng/mL for PPMS patients.
CSF NfL levels were non–detectable in this cohort. This might be due to the more
benign disease course or to the sensitivity of the NfL ELISA used.
The Amsterdam cohort — 3–year follow–up Three year follow–up data was
available from 34 of these patients, but only 29 agreed to a second LP [136]. 318
patients with non–inﬂammatory neurological disease were included as controls (it
was not considered to be ethical to perform a lumbar puncture in healthy volun-
teers). The mean age was 44.0 years for NfHSMI35 controls and 45.4 years for
NfHSMI34 controls. The age of the MS patients was 46.5 years for the entire co-
hort, 39.6 years for RRMS, 48.5 years for SP/PPMS patients (pooled from baseline
cohort because of small sample size). The relapse–free interval for the MS patients
was 14.0, 8.1, 16.0 months respectively. Baseline EDSS was 3.25, 1.5, 6.0 at base-
line and 4.5, 3.0, 5.5 at 3–year follow–up, respectively. At baseline median CSF
NfHSMI35 levels were 0.078 (0.08–0.61) ng/mL in all MS, 0.053 (0.011–0.139)
in RRMS and 0.095 (0.025–0.163) in SP/PPMS patients. At 3–year follow–up
median CSF NfHSMI35 levels were 0.113 (0.0–0.178) ng/mL in all MS, 0.0 (0.0–
0.12) in RRMS and 0.129 (0.0–0.209) in SP/PPMS patients. An increase of CSF
NfHSMI35 levels was observed in a signiﬁcantly higher proportion of SP/PPMS
(59%) compared to RRMS patients (14%) suggestive of accumulation of axonal
injury in the progressive phase of the disease.
23The higher CSF NfHSMI35 and NfHSMI34 levels in the control group compared to
MS patients is in line with the previous ﬁnding [31] that axonal injury in MS seems
not to be such a major pathology as observed in other neurological diseases. Be-
cause each group used different standards it is impossible to compare the absolute
values. Even within the same group values between 2 different NfL ELISA tech-
niques differed [71, 73].
5.3 Plasma NfHSMI35 studies
There are only 2 studies investigating plasma NfHSMI35 levels [137, 138]. The re-
sults should therefore be regarded with caution until conﬁrmed independently by
other groups, particularly with regard to cell–type speciﬁcity as mentioned above.
Acute optic neuritis This prospective study aimed to investigate the relationship
between loss and recovery of optic nerve function with surrogate markers for in-
ﬂammation and for axonal injury in patients with acute optic neuritis [137]. The
median plasma levels of NfHSMI35 were signiﬁcantly higher in the ON patients 170
(70–330) pg/mL compared to the controls 5 (0–94) pg/mL. In total 50% of ON
patients had plasma NfHSMI35 levels above cut–off (top value of controls). Plasma
NfHSMI35 levels were also higher in those 36% of patients with poor recovery of vi-
sual function (250 pg/mL) when compared to those with good recovery (9 pg/mL).
The Toulouse cohort This observational study included 30 MS patients with
RRMS treated with interferon¯ and aimed to investigate whether treatment re-
sponse could be related retrospectively to axonal and inﬂammatory pathology as
measured by surrogate markers [138]. There were 11 responders to treatment and
19 non–responders. Median plasma NfHSMI35 levels were signiﬁcantly higher in
the responders 300 (0.1–2,400) pg/mL and non–responders 500 (0.1-2,200) pg/ml
if compared to healthy controls 4.5 (0–31) pg/mL. This result remained signiﬁcant
on a categorical level where 58% of the responder and 72% of the non–responder
had levels above cut–off (top value of controls).
5.4 Correlation with disability scales
A weak correlation between CSF NfL and the EDSS was observed in the “acyclovir
trial” at baseline (Spearman’s R=0.27, p<0.05) and after 2 years (R=0.34, p<0.01)
but the graphs displaying this correlation were not presented [133] and no such
correlations were found in the “acute–relapse study” [134].
24The “dot–blot study” revealed a correlation of CSF NfL with the EDSS (Pearson’s
R=0.41, p<0.05) if only those patients with progressive disease (SP/PPMS) were
subjected to analysis [70]. The graphs displaying this correlation were not shown
and one might argue that the signiﬁcance of this correlation would be lost after
Bonferroni correction for multiple comparisons.
The “Amsterdam 3–year follow–up study” revealed a correlation between CSF
NfHSMI35 levels and the EDSS (R=0.54, p<0.01), an ambulation index measur-
ing gait (R=0.42, p<0.05) and the 9 hole PEG test (R=0.59, p<0.01). However, no
such correlations were found at baseline in either the original cohort (n=54) [76] or
the baseline values of the subgroup with 3–year follow–up data (n=39, unpublished
data).
The“acuteopticneuritisstudy”demonstratedanegativecorrelationbetweenNfHSMI35 and
visual acuity (VA) at the time of ﬁrst presentation (R=-0.67, p=0.01) [137].
Although it might be desirable from a publishing point of view to ﬁnd a correlation
between a clinical scale and CSF Nf levels, one needs to remember that not each le-
sion in the CNS translates into deﬁcit on a clinical scale. Additionally some clinical
deﬁcit might be caused by demyelination or conduction block alone. From a clini-
cal point of view it would be more important to identify those patients who are “at
risk” of developing progressive disease due to axonal loss with subsequent progres-
sion of disability. From a trial point of view rigorous inclusion criteria (i.e. patients
with early evidence for axonal degeneration) would help to avoid the potential for
selection bias in treatment trials for neuroprotective drugs by cohort contamination
with patients showing evidence for inﬂammation only (prone to bias by regression
to the mean).
Nf auto–antibody levels The work on anti–NfL and anti–NfH autoantibodies
has largely been done by E Silber using bovine NfL and NfH in an ELISA setup
[75, 76]. He discovered a 2–fold higher mean anti NfL index in PPMS (466) and
SPMS (499) patients compared to RR MS patients (208) or inﬂammatory controls
(169) [75]. For the anti NfH index the differences were less marked RRMS (381),
PPMS (455), SPMS (501) and inﬂammatory controls (155). The anti–NfL index
correlated with disease duration (Spearman’s R=0.42, p<0.0001) and the EDSS
(R=0.54, p<0.0001). Although these correlations are moderate at best, the ﬁgures
show that the ﬁndings were not based on outliers.
Applying his technique to the Amsterdam cohort at baseline we found a correla-
tion of the anti–NfL index with MRI measures such as the PF (Spearman’s R=-
0.51, p<0.001), the T1 lesion load (R=0.37, p<0.05), the T2 lesion load (R=0.41,
p<0.05) and the VF (R=0.37, p<0.05). For the anti-NfH index there was only a
correlation with the PF (R=-0.39, p<0.05). These correlations were mainly based
on the results for the RRMS subgroup were the anti-NfL index correlated with the
25PF, VF and T1LL (R=-0.56, p<0.05; R=0.72, p<0.01 and R=0.61, p<0.05, respec-
tively). However, the results for the T1 & T2 lesion load and VF were partly based
on 2–3 outliers [76]. With one exception (a weak correlation with the PF in the
whole cohort, R=-0.39, p<0.05) no such correlations were found for the anti–NfH
index [76].
5.4.0.1 Acknowledgements I am grateful to Dr Geoffrey Keir and Professor
Edward Thompson for comments on the manuscript.
5.4.0.2 Post scriptum Since submission of this review another study on CSF
NfH was published: Lim ET et al. “Cerebrospinal ﬂuid levels of brain speciﬁc
proteins in optic neuritis”, Mult Scler 2004;10:261–265.
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